Wu Kun, Zhao Lan, Li Yao, Shan Yu-Juan, Wu Li-Jie
Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin 150001, Heilongjiang Province, China.
World J Gastroenterol. 2004 Apr 1;10(7):945-9. doi: 10.3748/wjg.v10.i7.945.
To investigate the effects of vitamin E succinate (VES) on the expression of Fas and PCNA proteins as well as its clinical significance in human gastric carcinoma, and to explore the mechanism of VES-induced inhibition of gastric carcinoma cell growth.
Immunohistochemical methods were used to detect Fas and PCNA expression both in human gastric cancer SGC-7901 cells treated with VES at different doses and in human gastric carcinoma tissues.
After the SGC-7901 cells were treated with VES at 5, 10, 20 mg/L for 48 h, the positive rates of Fas expression were 16%, 27% and 48%, respectively, significantly increased compared to that of control group (P< 0.05); while the positive rates of PCNA expression in groups treated with different doses of VES were 20%, 18% and 7%, respectively, which were significantly decreased compared to that of the control group (P<0.05). In human gastric carcinoma tissues, the Fas positive expression rate was 42.4%(25/59), which declined with the decrease in the degree of tumor differentiation (P<0.05) and with the existence of lymph node metastasis (P<0.001). While the PCNA positive expression rate was 91.5%(54/59), no relationship was observed between PCNA expression and clinicopathologic parameters.
VES inhibited the growth of gastric cancer cells by inducing Fas expression and inhibiting PCNA expression. It is, therefore, considered that the expression of Fas and PCNA genes, through tumor cell apoptosis and proliferation, respectively, may be useful as a clinical predictive index in the application of VES to gastric carcinoma therapy, where as Fas may be of more value than PCNA.
探讨琥珀酸维生素E（VES）对人胃癌中Fas和PCNA蛋白表达的影响及其临床意义，探讨VES诱导胃癌细胞生长抑制的机制。
采用免疫组化方法检测不同剂量VES处理的人胃癌SGC-7901细胞及人胃癌组织中Fas和PCNA的表达。
SGC-7901细胞分别用5、10、20mg/L的VES处理48h后，Fas表达阳性率分别为16%、27%和48%，与对照组相比显著升高（P<0.05）；而不同剂量VES处理组PCNA表达阳性率分别为20%、18%和7%，与对照组相比显著降低（P<0.05）。在人胃癌组织中，Fas阳性表达率为42.4%（25/59），随肿瘤分化程度降低（P<0.05）及有淋巴结转移（P<0.001）而下降。而PCNA阳性表达率为91.5%（54/59），PCNA表达与临床病理参数之间无相关性。
VES通过诱导Fas表达和抑制PCNA表达抑制胃癌细胞生长。因此，认为Fas和PCNA基因的表达分别通过肿瘤细胞凋亡和增殖，可能作为VES应用于胃癌治疗的临床预测指标，而Fas可能比PCNA更有价值。
